Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy: A meta-analysis in Chinese population.
|
30544402 |
2018 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ERCC2 rs1799793 polymorphism is related to the high risk of osteosarcoma development.
|
30402838 |
2018 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that the T allele of ERCC2-rs1799793 and the A allele of ERCC3-rs4150441, interaction between rs1799793 and rs4150441, and haplotype containing the rs1799793T and rs11615-T alleles were all associated with increased osteosarcoma risk.
|
28474168 |
2017 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
|
28388903 |
2017 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated.
|
28977987 |
2017 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Future studies with larger sample sizes may contribute in elucidating the impact of ERCC2 and ERCC3 gene polymorphisms on osteosarcoma risks.
|
27051024 |
2016 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
|
26345951 |
2015 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our results suggest that ERCC1 rs11615 and ERCC2 rs1799793 may be useful genetic prognostic markers for osteosarcoma in a Chinese population.
|
26436406 |
2015 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our study found that the ERCC2 Asn312Asp gene polymorphism likely plays an important role in influencing the chemotherapy response and overall survival of patients with osteosarcoma.
|
26505449 |
2015 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Through quantitative analysis, the meta-analysis showed that ERCC2 Lys751Gln (ORGG vs. AA = 0.40 (95%CI = 0.1-0.86), P heterogeneity = 0.502; I (2) = 0 %) and ERCC5 His46His (ORCC vs. TT = 0.37 (95%CI = 0.15-0.93), P heterogeneity = 0.569; I (2) = 0 %) polymorphisms might influence the prognosis of patients with osteosarcoma [1].
|
25824708 |
2015 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
|
26400354 |
2015 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In summary, the ERCC2 Lys751Gln and ERCC5 His46His polymorphisms might influence osteosarcoma prognosis.
|
25023406 |
2014 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We first report associations of four SNPs, ERCC1 Asn118Asn, ERCC1 Gln504Lys, ERCC2 Asp312Asn and ERCC2 Lys751Gln, with risk of death from osteosarcoma in a Chinese population, indicating ERCC1 118T/T and ERCC2 A/A may be used as surrogate markers for clinical outcome of osteosarcoma treatment with cisplatin.
|
23098477 |
2012 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study suggests that XPD rs1799793 could be a marker of osteosarcoma associated with features conferring either a better prognosis or a better outcome after platinum therapy, or both.
|
21826087 |
2012 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study indicated that GSTP1 and ERCC2 Lys751Gln polymorphisms might be candidate pharmacogenomic factors to be explored in the future to identify osteosarcoma patients who might benefit from chemotherapy.
|
23317281 |
2012 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
|
19434073 |
2009 |